Commonwealth Equity Services LLC lowered its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,733 shares of the company’s stock after selling 147 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Henry Schein were worth $777,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Dupont Capital Management Corp lifted its stake in Henry Schein by 73.9% in the fourth quarter. Dupont Capital Management Corp now owns 546 shares of the company’s stock valued at $44,000 after buying an additional 232 shares during the period. Guardian Wealth Advisors LLC bought a new stake in Henry Schein in the third quarter valued at $51,000. Godsey & Gibb Inc. bought a new stake in Henry Schein in the fourth quarter valued at $64,000. Kistler Tiffany Companies LLC increased its stake in Henry Schein by 31.6% in the third quarter. Kistler Tiffany Companies LLC now owns 1,053 shares of the company’s stock valued at $69,000 after purchasing an additional 253 shares in the last quarter. Finally, Covestor Ltd increased its stake in Henry Schein by 88.4% in the first quarter. Covestor Ltd now owns 861 shares of the company’s stock valued at $75,000 after purchasing an additional 404 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.
Insider Activity at Henry Schein
In related news, Director Kurt P. Kuehn sold 1,909 shares of the stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $77.46, for a total transaction of $147,871.14. Following the completion of the sale, the director now directly owns 15,675 shares of the company’s stock, valued at $1,214,185.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Kurt P. Kuehn sold 1,909 shares of the stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $77.46, for a total transaction of $147,871.14. Following the completion of the transaction, the director now owns 15,675 shares in the company, valued at $1,214,185.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Mark E. Mlotek sold 24,747 shares of the stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $76.68, for a total transaction of $1,897,599.96. Following the transaction, the executive vice president now owns 69,138 shares of the company’s stock, valued at approximately $5,301,501.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,061 shares of company stock valued at $2,549,801. 1.14% of the stock is owned by insiders.
Henry Schein Stock Down 0.8 %
Henry Schein (NASDAQ:HSIC – Get Rating) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.02). The business had revenue of $3.06 billion for the quarter, compared to analysts’ expectations of $3.09 billion. Henry Schein had a net margin of 3.82% and a return on equity of 15.41%. The business’s revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.30 earnings per share. Research analysts expect that Henry Schein, Inc. will post 5.26 earnings per share for the current fiscal year.
Analyst Ratings Changes
HSIC has been the subject of a number of research reports. Barrington Research reduced their price objective on Henry Schein from $92.00 to $90.00 in a research note on Wednesday, May 10th. StockNews.com cut Henry Schein from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. UBS Group raised their price objective on shares of Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research note on Tuesday, March 7th. Piper Sandler boosted their target price on shares of Henry Schein from $85.00 to $97.00 and gave the stock an “overweight” rating in a research report on Monday, February 6th. Finally, Credit Suisse Group dropped their price target on shares of Henry Schein from $99.00 to $97.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Henry Schein presently has an average rating of “Hold” and an average target price of $85.67.
Henry Schein Company Profile
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Get Rating).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.